Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.58 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.55 |
| ▸ | PHGDH | O43175 | 4/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085708 | 0.89 | PTGER4 (0.48) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12585296 | 0.84 | PHGDH (0.56) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12585324 | 0.83 | PHGDH (0.54) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12585471 | 0.83 | PTGER4 (0.59) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12585740 | 0.82 | PTGER4 (0.56) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12585327 | 0.80 | PTGER4 (0.56) | PTGER4PTGDRPHGDHPTGER2 | |
| SCHEMBL12900406 | 0.79 | PTGER4 (0.84) | PTGER4PTGDRPTGER2 | |
| SCHEMBL987966 | 0.79 | PTGER4 (0.84) | PTGER4PTGDRPTGER2 | |
| SCHEMBL12585876 | 0.78 | PTGER4 (0.64) | PTGER4PHGDHPTGER2 | |
| SCHEMBL18435242 | 0.78 | PTGER4 (0.64) | PTGER4PHGDHPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460787-A1 | Amide compounds and their use as PGE2 antagonists. | Astellas Pharma Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028463-A1 | AMIDE COMPOUNDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 10/4885PHGDH 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.